Fibrocell Science, Inc. (OTCBB: FCSC) announced today that is has
submitted to the U.S. Food & Drug Administration (FDA) the company's
Phase II clinical study protocol to evaluate the safety and efficacy of
Fibrocell's lead therapy, azficel-T, in improving the range of motion,
function and flexibility, in patients with existing restrictive burn
scars.
"Submitting the study protocol to the FDA is an important step towards
evaluating a new potential therapeutic use for azficel-T, recently
approved by the FDA for the treatment of nasolabial fold wrinkles," said
Fibrocell's Chairman and CEO David Pernock. "Azficel-T is being studied
to assess its potential for addressing an unmet need in the treatment of
patients suffering with restrictive burn scars."
Study reveals daily food environment exposure shapes fast food habits